Literature DB >> 5922742

Disquisitions of Original Antigenic Sin. I. Evidence in man.

R G Webster.   

Abstract

When primary immunity is boosted not by the homologous but by a crossreacting vaccine, the newly formed antibodies react better with the primary antigen than with the antigen actually eliciting the response. This phenomenon bears the name of Original Antigenic Sin (1). It is shown that the number of antibody molecules produced against the original and the vaccinating antigen is the same; that each of these molecules is capable of reacting with both antigens; that the activity of an antiserum can be completely absorbed with either antigen; that both residual and adsorbed-dissociated fractions of antibody exhibit the same relative affinities towards the two antigens as did the native serum; that, unlike standard primary and secondary responses, the population of antibody molecules characterizing the Original Antigenic Sin is homogeneous; that each molecule has a lower equilibrium constant (i.e. higher avidity) against the original antigen than against the antigen stimulating the present response; and that all equilibrium constants are typical of secondary antibody. It is concluded that the Original Antigenic Sin is a partial anamnestic response, a related antigen stimulating that sector only of the originally primed cells which is destined to produce cross-reacting antibody. A hypothesis is developed according to which the basic difference between primary and secondary reactivity rests on the presence of a trapping mechanism that allows anamnestic production of antibody against lower doses of the homologous antigen. Such a mechanism is capable of cross-trapping related antigens, thus preventing a standard primary response and allowing manifestations of Original Antigenic Sin.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5922742      PMCID: PMC2138235          DOI: 10.1084/jem.124.3.331

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  IMMUNE TOLERANCE AND AN EXTRACELLULAR REGULATORY ROLE FOR BIVALENT ANTIBODY.

Authors:  H N EISEN; F KARUSH
Journal:  Nature       Date:  1964-05-16       Impact factor: 49.962

2.  Anamnestic responses in rabbits immunized with two related bacterial viruses.

Authors:  J G CAMPBELL
Journal:  Aust J Exp Biol Med Sci       Date:  1959-06

3.  Studies of antibodies to strains of influenza virus in persons of different ages in sera collected in a postepidemic period.

Authors:  A V HENNESSY; F M DAVENPORT; T FRANCIS
Journal:  J Immunol       Date:  1955-11       Impact factor: 5.422

4.  Heterogeneity of antibody sites in their relative combining affinities for structurally related haptens.

Authors:  A NISONOFF; D PRESSMAN
Journal:  J Immunol       Date:  1958-08       Impact factor: 5.422

5.  The current status of the control of influenza.

Authors:  T FRANCIS
Journal:  Ann Intern Med       Date:  1955-09       Impact factor: 25.391

6.  A serological recapitulation of human infection with different strains of influenza virus.

Authors:  T FRANCIS; F M DAVENPORT; A V HENNESSY
Journal:  Trans Assoc Am Physicians       Date:  1953

7.  Influenza: the new acquayantance.

Authors:  T FRANCIS
Journal:  Ann Intern Med       Date:  1953-08       Impact factor: 25.391

8.  Characterization of influenza antibodies by serum absorption.

Authors:  K E JENSEN; F M DAVENPORT; A V HENNESSY; T FRANCIS
Journal:  J Exp Med       Date:  1956-08-01       Impact factor: 14.307

9.  Antibody formation in vitro.

Authors:  M FISHMAN
Journal:  J Exp Med       Date:  1961-12-01       Impact factor: 14.307

10.  Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus.

Authors:  F M DAVENPORT; A V HENNESSY; T FRANCIS
Journal:  J Exp Med       Date:  1953-12       Impact factor: 14.307

View more
  206 in total

Review 1.  Mechanisms of immune escape in viral hepatitis.

Authors:  W Rosenberg
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 2.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Public versus personal serotypes of a viral quasispecies.

Authors:  Lukas Hunziker; Adrian Ciurea; Mike Recher; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-02       Impact factor: 11.205

4.  Epitope analysis for influenza vaccine design.

Authors:  Enrique T Muñoz; Michael W Deem
Journal:  Vaccine       Date:  2005-01-19       Impact factor: 3.641

5.  An analysis of the properties of monoclonal antibodies directed to epitopes on influenza virus hemagglutinin.

Authors:  L E Brown; J M Murray; D O White; D C Jackson
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals.

Authors:  D R Snodgrass; T A Fitzgerald; I Campbell; G F Browning; F M Scott; Y Hoshino; R C Davies
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

7.  Ab and T cell epitopes of influenza A virus, knowledge and opportunities.

Authors:  Huynh-Hoa Bui; Bjoern Peters; Erika Assarsson; Innocent Mbawuike; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-02       Impact factor: 11.205

8.  Quantifying influenza vaccine efficacy and antigenic distance.

Authors:  Vishal Gupta; David J Earl; Michael W Deem
Journal:  Vaccine       Date:  2006-01-19       Impact factor: 3.641

9.  Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo.

Authors:  P A Scherle; W Gerhard
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

Review 10.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.